aripiprazole has been researched along with Anxiety in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (25.00) | 29.6817 |
| 2010's | 14 (58.33) | 24.3611 |
| 2020's | 4 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Bojarski, AJ; Bucki, A; Byrtus, H; Czopek, A; Kalinowska-Tłuścik, J; Kazek, G; Kołaczkowski, M; Partyka, A; Pawłowski, M; Piaskowska, A; Wesołowska, A | 1 |
| Alda, M; Beaulieu, S; Berk, M; Bond, DJ; Calabrese, J; Chakrabarty, T; Frey, BN; Goldstein, BI; Kanba, S; Kapczinski, F; Kauer-Sant'Anna, M; Kennedy, SH; Kozicky, JM; Lam, RW; Malhi, G; McIntyre, RS; Milev, RV; O'Donovan, C; Parikh, SV; Post, R; Ravindran, AV; Rej, S; Schaffer, A; Sharma, V; Suppes, T; Tourjman, V; Vazquez, G; Vieta, E; Yatham, LN | 1 |
| Kiss, A; Koprdova, R; Mach, M; Osacka, J; Tillinger, A | 1 |
| Baldisserotto, B; Barcellos, HHA; Barcellos, LJG; Fernandes, M; Kirsten, K; Koakoski, G; Maffi, VC; Mendonça-Soares, S; Pompermaier, A | 1 |
| Cardiel-Sam, H; Shirk, DV; Wendel, N; Williams, SD | 1 |
| Adham, N; Banasr, M; Duman, RS; Duric, V; Franklin, T; Gyertyán, I; Kiss, B; Lepack, A | 1 |
| Baker, RA; Dunlop, BW; Eudicone, JM; McCabe, B; Sheehan, JJ | 1 |
| De Santis, M; Deng, C; Huang, XF; Lian, J | 1 |
| Giermaziak, W; Kus, K; Nowakowska, E; Ratajczak, P | 1 |
| Taylor, WD | 1 |
| Aizenstein, HJ; Anderson, SJ; Blumberger, D; Butters, MA; Dew, MA; Diniz, BS; Kaneriya, SH; Karp, JF; Lenze, EJ; Lotrich, F; Mulsant, BH; Reynolds, CF; Robbins-Welty, GA; Smagula, SF | 1 |
| Bieńkowski, P; Jastrzębska-Więsek, M; Kołaczkowski, M; Mierzejewski, P; Partyka, A; Wasik, A; Wesołowska, A | 1 |
| Abe, M; Egashira, N; Fujiwara, M; Iwasaki, K; Matsushita, M; Mishima, K; Nishimura, R; Oishi, R; Okuno, R | 1 |
| Bellino, S; Bogetto, F; Paradiso, E | 1 |
| Evenden, J; Jonak, G; Ross, L; Zhou, J | 1 |
| Biojone, C; Casarotto, PC; Guimarães, FS; Moreira, FA; Resstel, LB; Zangrossi, H | 1 |
| Aung, GL; Kawamoto, LS; O'Brien, JG; Tien, PG | 1 |
| Katzman, MA | 1 |
| Burda, K; Czubak, A; Kus, K; Nowakowska, E; Ratajczak, P; Zin, J | 1 |
| Cavanna, AE; Rickards, H; Worrall, R | 1 |
| Kurokawa, K; Mizuno, K; Ohkuma, S; Shibasaki, M | 1 |
| Kasper, S; Winkler, D | 1 |
| Amoretti, A; Di Lorenzo, R; Fiorini, F; Forghieri, M; Genedani, S; Rigatelli, M | 1 |
2 review(s) available for aripiprazole and Anxiety
| Article | Year |
|---|---|
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) recommendations for the management of patients with bipolar disorder with mixed presentations.
Topics: Antipsychotic Agents; Anxiety; Aripiprazole; Bipolar Disorder; Canada; Humans; Olanzapine; Valproic Acid | 2021 |
Aripiprazole: a clinical review of its use for the treatment of anxiety disorders and anxiety as a comorbidity in mental illness.
Topics: Anti-Anxiety Agents; Antipsychotic Agents; Anxiety; Anxiety Disorders; Aripiprazole; Bipolar Disorder; Depressive Disorder, Major; Drug Therapy, Combination; Humans; Mental Disorders; Piperazines; Quinolones | 2011 |
1 trial(s) available for aripiprazole and Anxiety
| Article | Year |
|---|---|
Predictors and Moderators of Remission With Aripiprazole Augmentation in Treatment-Resistant Late-Life Depression: An Analysis of the IRL-GRey Randomized Clinical Trial.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Anxiety; Aripiprazole; Comorbidity; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Executive Function; Female; Follow-Up Studies; Humans; Male; Middle Aged; Odds Ratio; Predictive Value of Tests; Prognosis; Risk Assessment; Risk Factors; Set, Psychology; Severity of Illness Index; Treatment Failure; Treatment Outcome; Venlafaxine Hydrochloride | 2016 |
21 other study(ies) available for aripiprazole and Anxiety
| Article | Year |
|---|---|
Novel spirohydantoin derivative as a potent multireceptor-active antipsychotic and antidepressant agent.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Antipsychotic Agents; Anxiety; Aripiprazole; Depression; Dextroamphetamine; Hydantoins; Hyperkinesis; Imidazolidines; Male; Mice; Piperazines; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine D2; Receptors, Serotonin; Structure-Activity Relationship; Swimming | 2015 |
Haloperidol and aripiprazole affects CRH system and behaviour of animals exposed to chronic mild stress.
Topics: Amygdala; Animals; Antipsychotic Agents; Anxiety; Aripiprazole; Behavior, Animal; Corticotropin-Releasing Hormone; Haloperidol; Male; Paraventricular Hypothalamic Nucleus | 2022 |
Aripiprazole prevents stress-induced anxiety and social impairment, but impairs antipredatory behavior in zebrafish.
Topics: Animals; Antipsychotic Agents; Anxiety; Aripiprazole; Cichlids; Female; Food Chain; Goldfish; Male; Predatory Behavior; Social Behavior; Stress, Physiological; Water Pollution, Chemical; Zebrafish | 2020 |
Topics: Angioedema; Antidepressive Agents; Anxiety; Aripiprazole; Black or African American; Child; Diphenhydramine; Histamine H1 Antagonists; Humans; Male; Nausea; Neck Pain | 2021 |
Cariprazine Exhibits Anxiolytic and Dopamine D3 Receptor-Dependent Antidepressant Effects in the Chronic Stress Model.
Topics: Anhedonia; Animals; Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Aripiprazole; Chronic Disease; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Imipramine; Male; Mice, Inbred C57BL; Mice, Knockout; Piperazines; Receptors, Dopamine D3; Stress, Psychological; Uncertainty | 2017 |
How well do clinicians and patients agree on depression treatment outcomes? Implications for personalized medicine.
Topics: Adult; Antidepressive Agents; Anxiety; Aripiprazole; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Piperazines; Precision Medicine; Prognosis; Psychiatric Status Rating Scales; Quinolones; Randomized Controlled Trials as Topic; Self Report; Treatment Outcome | 2014 |
Early antipsychotic treatment in childhood/adolescent period has long-term effects on depressive-like, anxiety-like and locomotor behaviours in adult rats.
Topics: Age Factors; Animals; Antipsychotic Agents; Anxiety; Aripiprazole; Behavior, Animal; Benzodiazepines; Depression; Female; Male; Motor Activity; Olanzapine; Rats; Rats, Sprague-Dawley; Risperidone; Sex Factors; Time Factors | 2016 |
The influence of aripiprazole and olanzapine on the anxiolytic-like effect observed in prenatally stressed rats (animal model of schizophrenia) exposed to the ethyl alcohol.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Aripiprazole; Behavior, Animal; Benzodiazepines; Disease Models, Animal; Ethanol; Female; Male; Olanzapine; Pregnancy; Prenatal Exposure Delayed Effects; Rats; Rats, Wistar; Schizophrenia; Stress, Psychological | 2016 |
Moderators of Remission in Patients With Late-Life Depression: Where Do We Go Next?
Topics: Antipsychotic Agents; Anxiety; Aripiprazole; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Executive Function; Female; Humans; Male; Set, Psychology | 2016 |
ADN-1184, a monoaminergic ligand with 5-HT6/7 receptor antagonist action, exhibits activity in animal models of anxiety.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Aripiprazole; Behavior, Animal; Benzodiazepines; Conditioning, Psychological; Conflict, Psychological; Disease Models, Animal; Dose-Response Relationship, Drug; Exploratory Behavior; Isoxazoles; Male; Maze Learning; Mice; Motor Activity; Olanzapine; Punishment; Rats, Wistar; Reaction Time; Receptors, Serotonin; Risperidone; Serotonin Antagonists; Sulfonamides | 2016 |
Aripiprazole inhibits marble-burying behavior via 5-hydroxytryptamine (5-HT)1A receptor-independent mechanisms.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antipsychotic Agents; Anxiety; Aripiprazole; Behavior, Animal; Benzodiazepines; Catalepsy; Dopamine Agonists; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Indoles; Ketanserin; Male; Mice; Mice, Inbred ICR; Olanzapine; Piperazines; Piperidines; Postural Balance; Psychomotor Performance; Pyridines; Quinolones; Quinpirole; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D2; Serotonin Antagonists; Serotonin Receptor Agonists | 2008 |
Efficacy and tolerability of aripiprazole augmentation in sertraline-resistant patients with borderline personality disorder.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Anxiety; Aripiprazole; Borderline Personality Disorder; Diagnostic and Statistical Manual of Mental Disorders; Drug Resistance; Drug Therapy, Combination; Headache; Humans; Middle Aged; Personality Inventory; Piperazines; Psychiatric Status Rating Scales; Quinolones; Sertraline; Severity of Illness Index; Sleep Initiation and Maintenance Disorders; Treatment Outcome | 2008 |
A novel operant conflict procedure using incrementing shock intensities to assess the anxiolytic and anxiogenic effects of drugs.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Aripiprazole; Benzodiazepines; Chlordiazepoxide; Conditioning, Operant; Conflict, Psychological; Dextroamphetamine; Diazepam; Electroshock; Flumazenil; Male; Piperazines; Punishment; Pyridazines; Quinolones; Rats; Rats, Sprague-Dawley; Triazoles; Yohimbine | 2009 |
Anti-aversive effects of the atypical antipsychotic, aripiprazole, in animal models of anxiety.
Topics: Animals; Anti-Anxiety Agents; Antipsychotic Agents; Anxiety; Aripiprazole; Conditioning, Psychological; Disease Models, Animal; Dose-Response Relationship, Drug; Fear; Male; Maze Learning; Motor Activity; Piperazines; Quinolones; Rats; Rats, Wistar | 2011 |
Increased aripiprazole concentrations in an HIV-positive male concurrently taking duloxetine, darunavir, and ritonavir.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Anxiety; Aripiprazole; Cytochrome P-450 Enzyme Inhibitors; Darunavir; Depression; Dose-Response Relationship, Drug; Duloxetine Hydrochloride; HIV Infections; HIV Protease Inhibitors; Humans; Male; Piperazines; Quinolones; Ritonavir; Sulfonamides; Thiophenes | 2010 |
Influence of aripiprazole on the antidepressant, anxiolytic and cognitive functions of rats.
Topics: Animals; Antipsychotic Agents; Anxiety; Aripiprazole; Behavior, Animal; Cognition; Depression; Disease Models, Animal; Male; Maze Learning; Memory; Piperazines; Quinolones; Rats; Rats, Wistar; Toxicity Tests | 2011 |
Treatment practices in Tourette syndrome: the European perspective.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Anxiety; Aripiprazole; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Clonidine; Depression; Europe; Fluoxetine; Fluvoxamine; Health Care Surveys; Humans; Methylphenidate; Obsessive-Compulsive Disorder; Physicians; Piperazines; Propylamines; Psychiatry; Quinolones; Risperidone; Sertraline; Sulpiride; Tourette Syndrome | 2012 |
Effect of aripiprazole on anxiety associated with ethanol physical dependence and on ethanol-induced place preference.
Topics: Alcoholism; Animals; Antipsychotic Agents; Anxiety; Aripiprazole; Behavior, Animal; Dopamine; Ethanol; Male; Mice; Piperazines; Pyridines; Quinolones; Substance Withdrawal Syndrome; Time Factors | 2012 |
Aripiprazole (Abilify) for schizophrenia.
Topics: Antipsychotic Agents; Anxiety; Aripiprazole; Dopamine Agonists; Drug Interactions; Fees, Pharmaceutical; Humans; Intestinal Absorption; Nausea; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Therapeutic Equivalency | 2003 |
European College of Neuropsychopharmacology - 16th Congress. 20-24 September 2003, Prague, Czech Republic.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Alzheimer Disease; Anxiety; Aripiprazole; Dopamine Antagonists; Humans; Nicotinic Agonists; Piperazines; Psychotropic Drugs; Quinolones; Receptors, Metabotropic Glutamate; Receptors, Nicotinic; Schizophrenia | 2003 |
Aripiprazole: effectiveness and safety under naturalistic conditions.
Topics: Adult; Antipsychotic Agents; Anxiety; Aripiprazole; Female; Humans; Inpatients; Italy; Male; Middle Aged; Outpatients; Piperazines; Psychiatric Status Rating Scales; Psychomotor Agitation; Psychotic Disorders; Quinolones; Recurrence; Retrospective Studies; Schizoid Personality Disorder; Schizophrenia, Paranoid; Schizotypal Personality Disorder; Sleep Initiation and Maintenance Disorders; Time Factors; Treatment Outcome | 2007 |